Accelerate Diagnostics reports Q3 2017 financial results
Nov 02, 2017
Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending September 30, 2017. The company further reported signed agreements for 295 instruments year to date; contracts for customer evaluations total 239 instruments while revenue generating placements grew to 56 across the U.S., European, and Middle East regions.
Net sales for the third quarter 2017 was $828,000 compared to $24,000 in the third quarter of 2016. The increase was driven by sales of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit.
- Accelerate Diagnostics, Inc. announced the election of Charles Watts, M.D. to the company’s board of directors. His appointment is effective November 14, 2017.
Nov 16, 2017
- New from LabRoots: Dr. Margie Morgan to present on the impact of fast phenotypic susceptibility results to laboratory workflow and patient outcomes
Nov 09, 2017